<DOC>
	<DOC>NCT01136707</DOC>
	<brief_summary>The purpose of this study is to examine the relationship between loading dose and adherence to Orencia.</brief_summary>
	<brief_title>Predictors of Adherence to Orencia</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Patients will be identified based on the presence of first infusion claim during study period for Orencia At least 1 medical or facility claim for rheumatoid arthritis at the time of or 6 months prior to index date Patients are required to be continuously enrolled for a minimum preindex and followup period as detailed below Patients with a minimum of 3 infusion claims for Orencia Only those patients will be included whose first 3 infusion claims occur within 84 days Patients less than 18 years of age at index date. One or more diagnoses of regional enteritis (including Crohn's disease), ulcerative colitis, anal or intestinal fistula, ankylosing spondylitis or other inflammatory spondylopathy, psoriatic arthropathy, or psoriasis any time during the 6month preindex period Patients who switch between biologics within their first three infusion claims Restarts, defined as those patients who go back on Orencia after a gap of 42 days Patients who are on other biologics at the same time as Orencia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>